Sanofi Gets Priority Review for Investigational Enzyme Therapy

The FDA has granted a priority review to Sanofi’s biologics license application (BLA) for an experimental enzyme replacement therapy for patients suffering from Pompe disease, a rare illness that causes muscle deterioration and reduced lung capacity.
Source: Drug Industry Daily